IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls

Adv Neurol. 1993:60:525-8.
No abstract available

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / therapeutic use
  • Benzamides / pharmacokinetics*
  • Corpus Striatum / diagnostic imaging*
  • Corpus Striatum / drug effects
  • Corpus Striatum / physiopathology
  • Dopamine D2 Receptor Antagonists*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology
  • Pyrrolidines / pharmacokinetics*
  • Receptors, Dopamine D2 / drug effects
  • Receptors, Dopamine D2 / physiology
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Antiparkinson Agents
  • Benzamides
  • Dopamine D2 Receptor Antagonists
  • Pyrrolidines
  • Receptors, Dopamine D2
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide